Biocryst Pharmaceuticals (BCRX) Total Debt Growth (1y) (2012 - 2026)
Biocryst Pharmaceuticals (BCRX) Total Debt Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | -3.69% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 37.49% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -2.48% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 4.38% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | -6.91% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | 41.53% |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.12 Bn | 214.41 Mn | 57.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.69% |
| Mar 31, 2026 | 24.53% |
| Dec 31, 2025 | -88.94% |
| Sep 30, 2025 | -33.19% |
| Jun 30, 2025 | -18.75% |
| Mar 31, 2025 | 4.55% |
| Dec 31, 2024 | 6.35% |
| Sep 30, 2024 | 16.56% |
| Jun 30, 2024 | 16.92% |
| Mar 31, 2024 | 43.86% |
| Dec 31, 2023 | 41.09% |
| Sep 30, 2023 | 33.11% |
| Jun 30, 2023 | 102.87% |
| Mar 31, 2023 | 65.81% |
| Dec 31, 2022 | -22.31% |
| Sep 30, 2022 | 69.53% |
| Jun 30, 2022 | 13.98% |
| Mar 31, 2022 | 13.98% |
| Dec 31, 2021 | 143.16% |
| Sep 30, 2021 | 186.81% |